Literature DB >> 12512240

Pharmacoepidemiologic implications of erroneous varicella vaccinations in pregnancy through confusion with Varicella zoster immune globulin.

Robert P Wise1, M Miles Braun, Jane F Seward, Gina Terracciano Mootrey, Kristine E Shields, Marcel E Salive, Philip R Krause.   

Abstract

A series of case reports to the varicella vaccine Pregnancy Registry described inadvertent administrations during pregnancy of this live virus product instead of the intended Varicella zoster immune globulin. Cases continued to accrue despite an early publication about the pattern. The persistent problem warrants specific educational efforts to prevent further repetitions. It also has more general implications for medical product safety surveillance. First, this problem's original detection depended on the Pregnancy Registry's open-ended collection of information about pregnancy exposures. It could have escaped recognition through surveillance limited to pre specified potential risks. This need for unrestricted reporting and human vigilance to sift through case stories has particular relevance for efforts to re-think methods to monitor gestational drug exposures. In addition, the problem's persistence despite initial publicity suggests that diligent surveillance may require continued follow-up of identified safety issues. Periodic reassessments of selected preventable problems might strengthen efforts to minimize product risks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12512240     DOI: 10.1002/pds.749

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

1.  Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.

Authors:  Kristine E Shields; Bengt-Erik Wiholm; Linda S Hostelley; Linda F Striano; Sam R Arena; Robert G Sharrar
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Preventable mix-ups of tuberculin and vaccines: reports to the US Vaccine and Drug Safety Reporting Systems.

Authors:  Soju Chang; Vitali Pool; Kathryn O'Connell; Jacquelyn A Polder; John Iskander; Colleen Sweeney; Robert Ball; M Miles Braun
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.